{"organizations": [], "uuid": "37f08ffcfda12905eaf530e9ae8edc751d772252", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180403.html", "section_title": "Archive News &amp; Video for Tuesday, 03 Apr 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-fda-accepts-biologics-license-appl/brief-fda-accepts-biologics-license-application-for-moxetumomab-pasudotox-idUSASC09UMP", "country": "US", "domain_rank": 408, "title": "BRIEF-FDA Accepts Biologics License Application For Moxetumomab Pasudotox", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.997, "site_type": "news", "published": "2018-04-03T19:07:00.000+03:00", "replies_count": 0, "uuid": "37f08ffcfda12905eaf530e9ae8edc751d772252"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-fda-accepts-biologics-license-appl/brief-fda-accepts-biologics-license-application-for-moxetumomab-pasudotox-idUSASC09UMP", "ord_in_thread": 0, "title": "BRIEF-FDA Accepts Biologics License Application For Moxetumomab Pasudotox", "locations": [], "entities": {"persons": [], "locations": [{"name": "us", "sentiment": "none"}], "organizations": [{"name": "fda", "sentiment": "negative"}, {"name": "reuters", "sentiment": "negative"}, {"name": "astrazeneca plc", "sentiment": "negative"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "April 3 (Reuters) - AstraZeneca PLC:\n* US FDA ACCEPTS BIOLOGICS LICENSE APPLICATION FOR MOXETUMOMAB PASUDOTOX IN HAIRY CELL LEUKEMIA\n* FDA GRANTED MOXETUMOMAB PASUDOTOX BLA PRIORITY REVIEW STATUS WITH A PRESCRIPTION DRUG USER FEE ACT DATE SET FOR Q3 OF 2018 Source text for Eikon: Further company coverage:\n ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-04-03T19:07:00.000+03:00", "crawled": "2018-04-04T12:16:35.007+03:00", "highlightTitle": ""}